Science Corporation valued at $1.5B after $230M Series C — CE mark expected mid-2026 with Germany as first market, expanding to Stargardt and RP
Summary
TechCrunch reported that Science Corporation's $230M Series C round granted the company a post-money valuation of $1.5 billion. Science Corp submitted a CE mark application for PRIMA to the EU and expects approval in mid-2026, following which Germany will be its first market — as Germany has established pathways for early access to new medical technologies. In the US, regulatory discussions with the FDA are ongoing. Science Corp is also expanding its PRIMA clinical trial program to include Stargardt disease and retinitis pigmentosa (RP) — inherited retinal conditions that are leading causes of vision loss in young adults. Additionally, Science Corp acquired MEMS (microelectromechanical systems) facility assets in North Carolina's Research Triangle Park, giving it in-house chip/MEMS manufacturing for neural interface devices — a rare capability among BCI startups.
Why it matters
In-house MEMS manufacturing capability is what separates Science Corporation from virtually every other BCI company. Manufacturing internally means faster iteration cycles, lower cost per unit at commercial scale, and protection of manufacturing process IP that cannot be obtained from outsourced foundries. The Germany-first commercial strategy is pragmatic: Germany has the largest medical technology market in Europe and PRIMA's early-access pathway avoids the 18-month HTA review that other EU countries require.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial